Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test | GenomeWeb

By Adam Bonislawski

Vermillion this week reported revenues of $344,000 for the second quarter, including $45,000 from product sales of its OVA1 protein biomarker-based ovarian cancer test – the first revenue the company has posted from sales of the test since its commercial launch on March 11.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.